Related Experiment Video
Updated: May 26, 2026

Dioscin Mediated IgA Nephropathy Alleviation by Inhibiting B Cell Activation In Vivo and Decreasing Galactose-Deficient IgA1 Production In Vitro
Published on: October 13, 2023
[Management of IgA nephropathy].
Luigi Amoroso1, Luisa De Sanctis, Paolo Cappelli
1Istituto di Clinica Nefrologica, Universita' ''G. D'Annunzio'', Chieti-Pescara, Italy. lamoroso@unich.it
Current IgA nephropathy treatments focus on managing symptoms, not curing the disease. Standard care includes ACE inhibitors or ARBs, corticosteroids, and sometimes immunosuppressants for progressive cases.
Area of Science:
- Nephrology
- Immunology
Context:
- IgA nephropathy (Berger's disease) is a common cause of end-stage renal disease.
- Its natural history and optimal treatment remain poorly defined.
Purpose:
- To review current treatment strategies for IgA nephropathy.
- To highlight the established and potential benefits of various therapeutic interventions.
Summary:
- Standard care involves angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) for antiproteinuric and renoprotective effects.
- Corticosteroids are effective in reducing proteinuria and renal injury.
- Cytotoxic immunosuppressants like cyclophosphamide and azathioprine may benefit rapidly progressive cases.
- Tonsillectomy is not currently recommended due to limited evidence on long-term renal survival.
Impact:
- Established the renoprotective roles of ACEIs/ARBs and corticosteroids in IgA nephropathy management.
- Identified a need for further research into novel therapeutic approaches based on disease pathogenesis.
More Related Videos
Related Concept Videos
Nephrotic Syndrome II : Assessment and Medical Management
Nephrotic Syndrome III : Nursing Management
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease IV: Nursing Management
Acute Kidney Injury VI: Nursing Management
Acute Kidney Injury V: Interprofessional Care

